Kodosaki, Eleftheria;
Zetterberg, Henrik;
Heslegrave, Amanda;
(2023)
Validating blood tests as a possible routine diagnostic assay of Alzheimer’s disease.
Expert Review of Molecular Diagnostics
10.1080/14737159.2023.2289553.
(In press).
Preview |
Text
Validating blood tests as a possible routine diagnostic assay of Alzheimer s disease.pdf - Published Version Download (1MB) | Preview |
Abstract
Introduction: In recent years, exciting developments in disease modifying treatments for Alzheimer’s disease (AD) have made accurate and timely diagnosis of this disease a priority. Blood biomarkers (BBMs) for amyloid pathology using improved immunoassay and mass spectrometry techniques have been an area of intense research for the last 10 years and are coming to the fore, as a real prospect to be used in the clinical diagnostics of the disease. // Areas covered: The following review will update and discuss blood biomarkers that will be most useful in diagnosing AD and the context necessary for their implementation. // Expert Opinion: It is clear we now have BBMs, and technology to measure them, that are capable of detecting amyloid pathology in AD. The challenge is to validate them across platforms and populations to incorporate them into clinical practice. It is important that implementation comes with education, we need to give clinicians the tools for appropriate use and interpretation. It is feasible that BBMs will be used to screen populations, initially for clinical trial entry but also therapeutic intervention in the foreseeable future. We now need to focus BBM research on other pathologies to ensure we accelerate the development of therapeutics for all neurodegenerative diseases.
| Type: | Article |
|---|---|
| Title: | Validating blood tests as a possible routine diagnostic assay of Alzheimer’s disease |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1080/14737159.2023.2289553 |
| Publisher version: | https://doi.org/10.1080/14737159.2023.2289553 |
| Language: | English |
| Additional information: | Copyright © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
| Keywords: | Alzheimer’s disease; blood biomarkers; immunoassay; diagnostics; amyloid; tau; neurofilament; GFAP |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10183243 |
Archive Staff Only
 |
View Item |
